Up-Conversion Y2O3:Yb(3+),Er(3+) Hollow Spherical Drug Carrier with Improved Degradability for Cancer Treatment

ACS Appl Mater Interfaces. 2016 Sep 28;8(38):25078-86. doi: 10.1021/acsami.6b07215. Epub 2016 Sep 14.

Abstract

The rare earth hollow spheres with up-conversion luminescence properties have shown potential applications in drug delivery and bioimaging fields. However, there have been few reports for the degradation properties of rare earth oxide drug carriers. Herein, uniform and well-dispersed Y2O3:Yb(3+),Er(3+) hollow spheres (YOHSs) have been fabricated by a general Pechini sol-gel process with melamine formaldehyde colloidal spheres as template. The novel YOHSs with up-conversion luminescence has good drug loading amount and drug-release efficiency; moreover, it exhibits pH-responsive release patterns. In particular, the YOHSs sample exhibits low cytotoxicity and excellent degradable properties in acid buffer. After the sample was loaded with anticancer drug doxorubicin (DOX), the antitumor result in vitro indicates that YOHS-DOX might be effective in cancer treatment. The animal imaging test also reveals that the YOHSs drug carrier can be used as an outstanding luminescent probe for bioimaging in vivo application prospects. The results suggest that the degradable drug carrier with up-conversion luminescence may enhance the delivery efficiency of drugs and improve the cancer therapy in clinical applications.

Keywords: Y2O3:Yb3+,Er3+ hollow spheres; cancer therapy; degradability; drug carrier; up-conversion luminescence.

MeSH terms

  • Animals
  • Doxorubicin
  • Drug Carriers / chemistry*
  • Drug Delivery Systems
  • Drug Liberation
  • Erbium
  • Luminescence
  • Neoplasms
  • Yttrium

Substances

  • Drug Carriers
  • Yttrium
  • Erbium
  • Doxorubicin
  • yttria